On July 4th, GuoLianHui reported that AbbVie, the American pharmaceutical factory, lowered its profit forecast for this year because the group needs to list additional research expenditures totaling 937 million US dollars for an acquisition. According to the company, according to the latest internal estimates, this quarter needs to include additional expenses related to acquisition, patent agreements, and joint research, totaling 937 million US dollars. The group's latest estimate is that the adjusted earnings per share in the second quarter are expected to range from 2.53 to 2.57 US dollars, originally at 3.05 to 3.09 US dollars: the adjusted earnings per share for this year will range from 10.61 to 10.81 US dollars, originally at 11.13 to 11.33 US dollars, and the market forecast is 11.25 US dollars. AbbVie will release its second quarter results on July 25th.
艾伯维下调次季及今年全年盈利预测
AbbVie lowers its profit forecast for the second quarter and full year of 2021.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.